Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ParkerVision, Inc.'s SEC filings document an OTCQB-traded Florida corporation focused on proprietary RF technologies, wireless applications, licensing, and patent enforcement. Its 8-K filings report operating results, legal and appellate developments involving patent claims, and material events that affect the company's capital structure and disclosure record.
The filing record also covers registered direct common stock offerings under a Form S-3 shelf registration statement, exchanges of convertible promissory notes for common stock, unregistered equity issuance disclosures, and executive compensation arrangements under the company's long-term incentive plan. These documents address governance approvals, share-based awards, financing terms, and risk references tied to patent proceedings and funding activity.
ParkerVision, Inc. updates its resale prospectus covering up to 12,800,000 shares of common stock, which may be sold from time to time by existing selling stockholders. The company will not receive proceeds from these resales, but could receive up to $800,000 in gross proceeds if an associated warrant is exercised for cash, which it expects to use for patent enforcement actions and general working capital.
The company also approved new nonqualified stock option grants under its 2019 Long-Term Incentive Plan. The CEO received a performance-based option for up to 8,000,000 shares and the CFO a performance-based option for up to 500,000 shares, both with a five-year performance period and a ten-year term, at an exercise price of $0.24 per share. Vesting is tied to cumulative net cash from patent enforcement actions and may accelerate if market capitalization reaches $1 billion for twenty consecutive trading days or upon a change in control. The CFO also received a time-based option for up to 500,000 shares vesting over two years, and both executives will receive a 2.5% cost-of-living base salary increase effective April 15, 2026.
ParkerVision, Inc. reported new compensation awards for its top executives. On January 22, 2026, the board’s compensation committee granted performance-based stock options under the 2019 Long-Term Incentive Plan, including an option to purchase up to 8,000,000 shares for CEO Jeffrey Parker and an option to purchase up to 500,000 shares for CFO Cynthia French.
The options have a five-year performance period with quarterly measurement dates, a ten-year term, and an exercise price of $0.24 per share, based on the last sale price on the grant date. Vesting depends on cumulative net cash the company receives from its patent enforcement actions after specified fees and repayments.
These performance options fully vest automatically if the company’s market capitalization reaches at least $1 billion for 20 consecutive trading days or upon a change in control. The committee also granted the CFO a separate time-based option for up to 500,000 shares at $0.24 per share, vesting in four equal biannual installments over two years beginning July 22, 2026, and approved a 2.5% cost-of-living increase in the base salaries of the CEO and CFO effective April 15, 2026.
ParkerVision, Inc. filed a prospectus supplement that continues to permit the resale by existing shareholders of up to 9,387,500 shares of common stock. These shares include 2,843,750 shares already issued under prior securities purchase agreements, 6,343,750 shares issuable upon conversion or interest payments on convertible notes at a fixed conversion price of $0.16 per share, and 200,000 shares issuable upon exercise of options granted for services. The company will not receive proceeds from shareholder resales but could receive up to $42,620 if the options are exercised for cash.
The supplement also incorporates a new Form 8-K, which reports that on November 24, 2025 ParkerVision completed a separate registered offering and sale of 16,481,579 common shares to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. No underwriters, placement agents, brokers, or finders were engaged, and no commissions or fees were paid.
ParkerVision, Inc. has a prospectus supplement allowing the selling shareholders to resell up to 16,638,353 shares of common stock issuable upon conversion and interest payments on certain 2022 convertible notes with a fixed conversion price of $0.13 per share. The supplement incorporates a new Form 8-K that reports a separate capital raise completed on November 24, 2025.
In that transaction, the company sold 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its effective shelf registration statement on Form S-3. No underwriters, placement agents, brokers, or finders were involved, so no commissions or fees were paid. A subscription agreement and a press release describing the closing are filed as exhibits.
ParkerVision, Inc. is registering for resale up to 1,578,946 shares of common stock under a prospectus supplement that also incorporates a recent equity financing update. The registered amount includes 1,052,631 outstanding shares of common stock and 526,315 shares issuable upon exercise of warrants issued under a December 14, 2021 securities purchase agreement. The company will not receive any proceeds from resale of these shares, but could receive up to $526,315 in gross proceeds if the warrants are exercised for cash, which it plans to use for general working capital, including litigation expenses. Separately, ParkerVision completed a primary offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off its shelf registration statement without underwriters or fees.
ParkerVision, Inc. has filed a prospectus supplement covering the resale of up to 13,342,953 shares of common stock by selling stockholders. These shares include 7,962,722 shares issued under prior securities purchase agreements, 3,230,942 shares plus 1,619,289 warrant shares from March 29, 2021 agreements, and 530,000 shares issued as payment for services. The company will not receive proceeds from resales, but could receive up to $2,833,756 in gross proceeds if the related warrants are exercised for cash, which it expects to use for working capital and litigation expenses.
The supplement also attaches a Form 8-K describing a completed offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, conducted off the company’s shelf registration statement. No underwriters, placement agents, brokers, or finders were used, and no commissions or fees were paid in connection with this primary offering.
ParkerVision, Inc. has filed a prospectus supplement tied to an existing resale registration that permits selling stockholders to resell up to 5,871,584 shares of its common stock issued under prior securities purchase agreements. The company will not receive any proceeds from these resale transactions. The supplement updates the prospectus by incorporating a new Form 8-K.
The attached Form 8-K reports that on November 24, 2025, ParkerVision completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its shelf registration statement on Form S-3. The company conducted this primary offering without underwriters, placement agents, brokers, or finders and paid no commissions or fees.
ParkerVision, Inc. updated its April 2020 resale prospectus to cover up to 16,809,295 shares of common stock that may be sold from time to time by existing stockholders. These shares include stock already issued, shares issuable from convertible notes, and up to 5,200,000 shares underlying warrants held by Aspire Capital and Tailwinds. The company will not receive proceeds from stockholder resales, but could receive up to $3,900,000 if the Aspire and Tailwinds warrants are exercised for cash.
Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its shelf registration statement. The company did not use underwriters or pay commissions in this transaction, and disclosed the closing and related agreements through its Form 8-K and attached exhibits.
ParkerVision, Inc. has an effective prospectus supplement that permits the resale by existing stockholders of up to 18,014,164 shares of common stock. These consist of up to 5,457,583 shares issuable under Tranche 1 convertible notes at a fixed conversion price of $0.10 per share, up to 10,131,581 shares issuable under Tranche 2 convertible notes at a fixed conversion price of $0.08 per share, 625,000 shares issued for services under the Fisher Consulting Agreement, and up to 1,800,000 shares issuable upon exercise of the Park Consulting Warrant with a $0.10 exercise price.
The company will not receive proceeds from resale of these shares by selling stockholders, but could receive up to $180,000 in gross proceeds if the Park Consulting Warrant is exercised for cash. Separately, ParkerVision completed a registered offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132 under its Form S-3 shelf registration statement, with no commissions or fees paid.
ParkerVision, Inc. has filed a prospectus supplement covering the resale by existing stockholders of up to 17,189,660 shares of common stock. These shares include stock and warrants from a 2016 private placement, shares issued and issuable under a 2018 PIPE agreement with Aspire Capital, and shares issuable upon conversion of 2018 convertible notes. The company will not receive proceeds from stockholder resales, but could receive up to $700,000 from cash exercises of a 2016 warrant and up to $1,763,500 from sales of common stock or warrant exercises under the Aspire Capital agreement.
Separately, ParkerVision completed a registered direct offering of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132, using its Form S-3 shelf registration. No underwriters, placement agents, brokers, or finders were involved and no commissions or fees were paid.